Pharma BD Deal Intelligence
Daiichi Sankyo to acquire Ambit Biosciences for $15 per share plus CVR worth up to $4.50 for total deal value of approximately $410 million
EHA survival data sets Daiichi Sankyo quizartinib back on track after earlier setbacks in FLT3-positive acute myeloid leukemia trials
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Daiichi Sankyo acquired Ambit Biosciences for ~$410M for cancer compound quizartinib.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Daiichi Sankyo Company, Limited / Ambit Biosciences (this deal) | 2006 | $410M | 62 |
| Daiichi Sankyo Company, Limited / Zepharma Inc. | 2006 | $200M | 57 |
| Daiichi Sankyo Company, Limited / Plexxikon Inc. | 2011 | $935M | 51 |
| Daiichi Sankyo Company, Limited / Ranbaxy Laboratories Limited | 2008 | $4.6B | 14 |
| Daiichi Sankyo Company, Limited / Nosis Biosciences, Inc. | 2025 | — | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
← Browse all deals · How we score deals
More: 2006 deals · Daiichi Sankyo Company, Limited deals · Oncology deals